GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

In a regulatory filing earlier, GeoVax disclosed that on April 11, the company received written notification from Advanced Technology ...

Citigroup Inc. C +3.20% + Free Alerts posted better-than-expected earnings for its first quarter. Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.41% to 40,689.26 while the NASDAQ ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office ...